Poietis, the biotech jewel in Bordeaux’s crown and world leader in 4D bioprinting solutions, has just launched a new bioprinting platform dedicated to industrial and R&D applications.
The first company in the world to develop biological tissue with laser bioprinting
Based on research from the University of Bordeaux, Poietis is a biotech company in Pessac, specializing in the design of regenerative medical therapies through 4D laser-assisted bioprinting.
Poietis’ bioprinting technology, of which the company holds a world exclusive license, is based on 10 years of innovative research conducted by Inserm and the University of Bordeaux.
Poietis was the prize-winner of the iLab Challenge in 2014 and Concours Mondial de l’Innovation in 2016.
4D bioprinting involves programming the self-organization of tissue while designing tissue component organizations (cells and extracellular matrix) which evolve in a controlled manner until specific biological functions emerge.
Poietis is currently developing 3D physiological models and establishing partnerships with major pharmaceutical and cosmetic groups such as BASF and L’Oréal.
After a first fundraiser of €2.5M in 2015, Poeitis is pursuing its development and is planning on strengthening its engineering team (22 employees).
A unique human skin bioprinting platform reaching the industrial stage
Poietis’ new laser-assisted bioprinting platform enables industrialists and researchers to design and manufacture biological tissues with a cellular resolution.
Dedicated to tissue model production for cosmetics manufacturers and pharmaceutical firsm, it also enables the development and the preclinical evaluation of bioprinted tissue for regenerative medicine.
(Source: Press release 11/05/17)